Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03251417
Other study ID # AHEAD-HBE002
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date September 10, 2017
Est. completion date April 25, 2021

Study information

Verified date January 2023
Source Peking University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Esophageal cancer is a common malignant disease worldwide especially in china. Though esophagectomy and definitive chemoradiotherapy are standard treatments, disease relapses in many patients and the prognosis of metastatic ESCC is still poor. For patients with unresectable or metastatic ESCC, chemotherapy is an important treatment alone or with radiotherapy. Taxane, platinum, and fluoropyrimidine have been reported effective in ESCC and is used as first-line treatment of ESCC. As for 2nd-line treatment, both irinotecan and taxane had been recommended based on data from clinical trials which were most enrolled esophageal or esophageal-gastric junction adenocarcinoma and with only small sample size. Therefore, it is still urgently needed to explore effective 2nd-line treatment for ESCC. Apatinib, also known as YN968D1, is an orally antiangiogenic agents. Preclinical and clinical data had shown that it is effective in the treatment of a variety of solid tumors including esophageal cancer. It had been approved as a 3rd-line treatment for patients with advanced gastric cancer by state FDA of China in 2014. And the safety data showed that hemorrhage is rare and non-fetal which is different from bevacizumab. Therefore, the investigators initialize this phase II study to explore the efficacy and safety of irinotecan and apatinib combination treatment in unresectable or metastatic ESCC patients who failed in 1st-line chemotherapy or chemoradiotherapy.


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date April 25, 2021
Est. primary completion date April 25, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Age 18 to 70 years. Both genders are eligible. - Patients must have histologically confirmed esophageal squamous cell carcinoma with unresectable or metastatic disease. - With measurable or evaluable disease defined by RECIST 1.1 criteria by multi-slice spiral CT or MR scan. - Failed in or disease progressed after fist-line chemotherapy (A. If failed in preoperative chemotherapy / chemoradiotherapy or disease progressed in 24 weeks after esophagectomy, the preoperative chemotherapy/ chemoradiotherapy is regard as first-line chemotherapy. B. If failed in definitive chemoradiotherapy or disease progressed in 24 weeks after definitive chemoradiotherapy, the definitive chemoradiotherapy is regard as first-line chemotherapy; C. If failed in or relapse in 24 weeks after adjuvant chemotherapy, the adjuvant chemotherapy is regard as first line chemotherapy). - Patients must have a performance status of 0-2 on the ECOG scale. - Life expectancy =3 months. - With normal marrow, liver and renal function:a hemoglobin (HGB) of =110g/L (without blood transfusion during 14 days); a neutrophil count of =2.0×109/L; a platelet count of =100×109/L; a total bilirubin (TBil) of =1.5 upper normal limitation (UNL) or =3 UNL in case of liver metastasis. a creatinine (Cr) of = 1.5 UNL or a creatinine clearance rate = 50ml/min (Cockcroft-Gault); a alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of =2.5 UNL or =5 UNL in case of liver metastasis. Fecal occult blood (-); Urine test: protein<(++) or <1.0g per 24 hours. - Without bleeding and thrombosis disease. - With normal coagulation function: APTT, PT and INR, each = 1.5 ULN - With normal electrocardiogram results and no history of congestive heart failure. - Female subjects of child-bearing potential must agree to use contraceptive measures starting 1 week before the administration of the first dose of apatinib until 8 weeks after discontinuing study drug. Male subjects must agree to use contraceptive measures during the study and 8 weeks after last dose of study drug. - With good compliance and agree to accept follow-up of disease progression and adverse events. - With written informed consent signed voluntarily by patients themselves or their supervisors witted by doctors. Exclusion Criteria: - Patients who have received irinotecan or apatinib in previous treatment. - Other pathological type cancers of esophagus except for squamous cell carcinoma - Uncontrolled hypertension (Treatment of antihypertensive drugs cannot reduced to the normal range: systolic pressure =140 mmHg and diastolic pressure =90 mmHg) - With =grade 2 coronary heart disease, arrhythmia (including QTc interval prolongation male >450 ms, women >470 ms) - Cannot take oral tables including uncontrolled vomiting, chronic diarrhea and intestinal obstruction. - With potential bleeding risk of GI including (1) peptic ulcer and fecal occult blood (++ - +++); (2) melena or hematemesis history in last 3 months;(3) In case of fecal occult blood (+) or (+/-),fecal occult blood examination must be repeat in one week. If fecal occult blood is still (+) or (+/-),endoscopy is required and if there are ulcer or other diseases with bleeding risk in the opinion of the investigators. (4) Primary tumour lesion is of deep ulcer and in the opinion of the investigators may place the patient at risk of fetal bleeding or GI perforation. - Urine test: protein>(++) or >1.0g per 24 hours. - With abnormal coagulation function (INR>1.5 ULN, APTT>1.5 ULN), - With thrombosis or receiving anticoagulant treatment. - With serious diseases such as congestive heart failure, uncontrolled myocardial infarction and arrhythmia, liver failure and renal failure. - With brain metastasis - Pregnant or lactated women.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Irinotecan
Irinotecan 150mg/m2, repeated very 2 weeks for 3 to 6 cycles.
Apatinib
Apatinib 500 mg oral take, daily

Locations

Country Name City State
China Beijing Cancer Hospital / Peking University Cancer Hospital Beijing Beijing

Sponsors (2)

Lead Sponsor Collaborator
Peking University Peking University Cancer Hospital & Institute

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease control rate The percentage of patients with CR, PR, and SD response after 3 cycles' treatment according to RESIST v1.1 criteria. From enrollment to 3 months after treatment.
Secondary Safety: All reported adverse events (NCI CTCAE 4.0 criteria) All reported adverse events (NCI CTCAE 4.0 criteria) during treatment and one months after treatment. From enrollment to progression of disease or 1 months after treatment.
Secondary Objective response rate Clinical response rate of treatment (CR+PR) according to RESIST v1.1 criteria From enrollment to 3 months after treatment
Secondary Median progression-free survival time The length of time from enrollment until the time of progression of disease From enrollment to progression of disease. Estimated time is about 4 months
Secondary Median overall survival time The length of time from enrollment until the time of death. From enrollment to death of patients, estimated about 8 months.
See also
  Status Clinical Trial Phase
Recruiting NCT06056336 - Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma Phase 2
Suspended NCT04084158 - A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Not yet recruiting NCT05561699 - Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer N/A
Active, not recruiting NCT04543617 - A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy Phase 3
Recruiting NCT06190782 - Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor Phase 3
Completed NCT05557955 - Identification of Breath Biomarkers in Esophageal Cancer
Recruiting NCT04045496 - A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Not yet recruiting NCT03766178 - Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT02913066 - S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma Phase 2
Completed NCT02399306 - Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma Phase 3
Completed NCT01605305 - Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer Phase 2
Not yet recruiting NCT05552651 - Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT05520619 - Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) Phase 2
Recruiting NCT05990231 - Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy Phase 2
Recruiting NCT04644250 - Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma Phase 2
Completed NCT02916511 - Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma Phase 2
Terminated NCT04032704 - A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Phase 2
Active, not recruiting NCT04063683 - Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC). Phase 2